Mechanistic clinical trial of blocking the IL-4/13 axis in asthmatics precision phenotyped in an aeroallergen challenge chamber before, during and after receipt of dupilumab

在接受 dupilumab 之前、期间和之后在空气过敏原激发室中精确表型的哮喘患者中阻断 IL-4/13 轴的机制临床试验

基本信息

  • 批准号:
    10686198
  • 负责人:
  • 金额:
    $ 118.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-18 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

7. Project Summary/Abstract We propose a high-impact, randomized, double-blind, placebo-controlled, mechanistic clinical trial aimed at elucidating the basis for the wide heterogeneity in severity of and treatment responses in persons with allergic rhinoconjunctivitis (ARC) and allergic asthma (AA). AA and ARC are highly prevalent, environmentally triggered and often comorbid conditions that share mechanistic correlates. We will study persons with house dust mite (HDM)-associated PARC and AA, termed HDM+PARC+AA+. HDMs are influential in AA/ARC pathogenesis and disease severity. To investigate mechanisms that may contribute to heterogeneity, we capitalized on an aeroallergen challenge chamber (ACC), a unique and relatively rare resource, which allows for controlled exposures to disease triggers of ARC/AA. Challenge studies with a fixed dose of HDM in persons with HDM- associated PARC without AA evoked (i) maladaptive (persistently higher ARC symptoms), (ii) adaptive (progressive symptom reduction with repeated challenges), and (ii) resilient (resistance to symptom induction) phenotypes. Symptom severity in the natural environment was an imprecise correlate of the phenotypes. Congruently, challenge studies in HDM+PARC+AA+ persons with HDMs in the ACC also evoked these phenotypes. Mechanistic studies revealed that these phenotypes may relate to an imbalance between levels of airway epithelial integrity and inflammation. To further test this concept, we will evaluate 88 HDM+PARC+AA+ persons with persistent mild-to-moderate asthma. The ACC will be used identify persons with the maladaptive and adaptive phenotypes, defined by higher and lower symptom severity evoked in response to HDM exposures in the ACC. Each phenotype strata will be randomized 1:1 and administered a 22-week course of dupilumab (monoclonal antibody targeting IL-4 receptor alpha) or placebo. Exposure to HDMs in an ACC for 1 daily 5-hour challenge will occur: 1) for phenotyping and baseline assessment of symptoms (pre-randomization), 2) intermittently while on dupilumab/placebo administration for assessment of heterogeneity in responses to drug, and 3) intermittently while off dupilumab/placebo for assessment of heterogeneity in the recrudescence in symptoms. Mechanistic correlates of the upper airway (nasal) and systemic (peripheral blood) compartments will be determined pre-treatment, on-treatment, and off-treatment. Thus, this clinical trial will test the hypothesis that a 22-week course of dupilumab will attenuate AA/ARC symptoms in persistent mild-to-moderate allergic asthmatic subjects by mitigating inflammation with or without fully restoring epithelial integrity. However, the rate of symptom attenuation and recrudescence will be less and greater, respectively, in persons with the maladaptive compared with adaptive phenotypes. Affirmation of this hypothesis will provide new insights into the mechanisms underpinning heterogeneity in disease severity and treatment responses, as well as provide a basis to consider multi-modal therapeutic interventions to achieve durable suppression of AA/ARC symptoms.
7.项目总结/摘要 我们提出了一个高影响力,随机,双盲,安慰剂对照,机械临床试验,旨在 阐明了过敏性鼻炎患者的严重程度和治疗反应的广泛异质性的基础, 鼻结膜炎(ARC)和过敏性哮喘(AA)。AA和ARC非常普遍,由环境引发 并且常常是共享机械相关性的共病状况。我们将研究患有屋尘螨的人 (HDM)相关的PARC和AA,称为HDM+PARC+AA+。HDM在AA/ARC发病机制中有影响, 疾病严重程度。为了研究可能导致异质性的机制,我们利用了一个 空气过敏原激发室(ACC),一种独特且相对罕见的资源, 暴露于ARC/AA的疾病触发因素。在HDM患者中进行的固定剂量HDM激发研究- 无AA的相关PARC诱发(i)适应不良(持续较高的ARC症状),(ii)适应性 (反复挑战的渐进性症状减轻)和(ii)弹性(对症状诱导的抵抗力) 表型在自然环境中的症状严重程度是一个不精确的相关表型。 相应地,在ACC中存在HDM的HDM+PARC+AA+患者中进行的激发研究也诱发了这些 表型机制研究表明,这些表型可能与以下水平之间的不平衡有关: 气道上皮完整性和炎症。为了进一步测试这一概念,我们将评估88 HDM+PARC+AA+ 患有持续性轻度至中度哮喘的人。ACC将用于识别适应不良的人 和适应性表型,定义为对HDM暴露的反应引起的较高和较低的症状严重程度 每个表型分层将以1:1随机分配,并给予22周疗程的dupilumab (靶向IL-4受体α的单克隆抗体)或安慰剂。在ACC中暴露于HDM,每天1次,每次5小时 将进行激发:1)用于表型分析和症状基线评估(随机化前),2) 在dupilumab/安慰剂给药期间间歇性评估药物应答异质性, 和3)间歇性停用dupilumab/安慰剂,以评估 症状上气道(鼻)和全身(外周血)室的机制相关性 将在治疗前、治疗中和治疗结束时确定。因此,这项临床试验将测试假设 dupilumab 22周疗程将减轻持续性轻度至中度过敏性鼻炎患者的AA/ARC症状。 哮喘受试者通过减轻炎症而具有或不具有完全恢复上皮完整性。然而, 的症状减轻和复发将分别更少和更大,在人与适应不良 与适应性表型相比。对这一假说的肯定将为研究其作用机制提供新的思路 支持疾病严重程度和治疗反应的异质性,并提供考虑 多模式治疗干预,以实现AA/ARC症状的持久抑制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sunil K Ahuja其他文献

Sunil K Ahuja的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sunil K Ahuja', 18)}}的其他基金

Mechanistic clinical trial of blocking the IL-4/13 axis in asthmatics precision phenotyped in an aeroallergen challenge chamber before, during and after receipt of dupilumab
在接受 dupilumab 之前、期间和之后在空气过敏原激发室中精确表型的哮喘患者中阻断 IL-4/13 轴的机制临床试验
  • 批准号:
    10488483
  • 财政年份:
    2022
  • 资助金额:
    $ 118.35万
  • 项目类别:
Host Genetic Determinants of HIV Pathogenesis
HIV发病机制的宿主遗传决定因素
  • 批准号:
    8119291
  • 财政年份:
    2010
  • 资助金额:
    $ 118.35万
  • 项目类别:
Host genetic determinants of HIV-AIDS susceptibility in a VA cohort
VA 队列中 HIV-AIDS 易感性的宿主遗传决定因素
  • 批准号:
    8597354
  • 财政年份:
    2009
  • 资助金额:
    $ 118.35万
  • 项目类别:
Host genetic determinants of HIV-AIDS susceptibility in a VA cohort
VA 队列中 HIV-AIDS 易感性的宿主遗传决定因素
  • 批准号:
    8391570
  • 财政年份:
    2009
  • 资助金额:
    $ 118.35万
  • 项目类别:
Host genetic determinants of HIV-AIDS susceptibility in a VA cohort
VA 队列中 HIV-AIDS 易感性的宿主遗传决定因素
  • 批准号:
    7908824
  • 财政年份:
    2009
  • 资助金额:
    $ 118.35万
  • 项目类别:
Host genetic determinants of HIV-AIDS susceptibility in a VA cohort
VA 队列中 HIV-AIDS 易感性的宿主遗传决定因素
  • 批准号:
    7797897
  • 财政年份:
    2009
  • 资助金额:
    $ 118.35万
  • 项目类别:
HOST GENETIC DETERMINANTS OF HIV PATHOGENESIS
HIV发病的宿主遗传决定因素
  • 批准号:
    7349823
  • 财政年份:
    2006
  • 资助金额:
    $ 118.35万
  • 项目类别:
HOST GENETIC DETERMINANTS OF HIV PATHOGENESIS
HIV发病的宿主遗传决定因素
  • 批准号:
    7165380
  • 财政年份:
    2005
  • 资助金额:
    $ 118.35万
  • 项目类别:
Genetic Epidemiology of HAD Susceptibility Genes
HAD易感基因的遗传流行病学
  • 批准号:
    6802143
  • 财政年份:
    2004
  • 资助金额:
    $ 118.35万
  • 项目类别:
Genetic Epidemiology of HAD Susceptibility Genes
HAD易感基因的遗传流行病学
  • 批准号:
    7154049
  • 财政年份:
    2004
  • 资助金额:
    $ 118.35万
  • 项目类别:

相似海外基金

Study on the Effects of Activation-induced cell death of ILC2s in Patients with Allergic Rhinitis
ILC2s激活诱导细胞死亡对变应性鼻炎患者影响的研究
  • 批准号:
    23K08954
  • 财政年份:
    2023
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New mechanisms of sublingual immunotherapy for the treatment of allergic rhinitis
舌下免疫治疗治疗变应性鼻炎的新机制
  • 批准号:
    22H03233
  • 财政年份:
    2022
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Testing the effectiveness of the biological drug, Tezepelumab, in patients with coexisting allergic rhinitis and allergic asthma
测试生物药物 Tezepelumab 对同时患有过敏性鼻炎和过敏性哮喘的患者的有效性
  • 批准号:
    490921
  • 财政年份:
    2022
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Studentship Programs
The analysis of T follicular helper and regulatory cells of patients with atopic asthma comorbid with allergic rhinitis by treated with HDM-SLIT
HDM-SLIT治疗特应性哮喘合并变应性鼻炎患者滤泡辅助T及调节细胞分析
  • 批准号:
    21K08441
  • 财政年份:
    2021
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Involvement of Neuromedin U in the pathogenesis of allergic rhinitis and analysis for innovative drug discovery.
Neuromedin U 参与过敏性鼻炎的发病机制以及创新药物发现的分析。
  • 批准号:
    20K09720
  • 财政年份:
    2020
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of clock genes and associated pathologies in the regulation of allergic rhinitis condition via the activation of Sirtuin1 signalling pathway.
时钟基因和相关病理通过激活 Sirtuin1 信号通路调节过敏性鼻炎病情的机制。
  • 批准号:
    20K18301
  • 财政年份:
    2020
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effect of IL-33 Gene Expression suppression on allergic rhinitis
IL-33基因表达抑制对变应性鼻炎的影响
  • 批准号:
    20K09693
  • 财政年份:
    2020
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Treatment of allergic rhinitis with intranasal NB-UVB irradiation
鼻内NB-UVB照射治疗过敏性鼻炎
  • 批准号:
    20K18254
  • 财政年份:
    2020
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the Effects of Aging Changes on the Pathophysiology of Allergic Rhinitis
阐明衰老变化对过敏性鼻炎病理生理学的影响
  • 批准号:
    20K22995
  • 财政年份:
    2020
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Novel diagnostic and preventive methods for allergic rhinitis using epigenetic analysis of nasal epithelial cells
利用鼻上皮细胞表观遗传学分析诊断和预防过敏性鼻炎的新方法
  • 批准号:
    20K18275
  • 财政年份:
    2020
  • 资助金额:
    $ 118.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了